beta

UMRX

Unum Therapeutics, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Market Cap: 9.8 Million

Primary Exchange: NASDAQ

Website: http://www.unumrx.com

Shares Outstanding: 30.6 Million

Float: 13.6 Million

Dividend: (%)

Beta: 0.602084834188305

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 947 trading days

From: 2018-07-31 To: 2020-04-03

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud